BR0207178A - 4-flúor-n-indan-2-ii-benzamida e seu uso farmacêutico - Google Patents
4-flúor-n-indan-2-ii-benzamida e seu uso farmacêuticoInfo
- Publication number
- BR0207178A BR0207178A BR0207178-9A BR0207178A BR0207178A BR 0207178 A BR0207178 A BR 0207178A BR 0207178 A BR0207178 A BR 0207178A BR 0207178 A BR0207178 A BR 0207178A
- Authority
- BR
- Brazil
- Prior art keywords
- indan
- benzamide
- pharmaceutical use
- prophylaxis
- therapy
- Prior art date
Links
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 201000001068 Prinzmetal angina Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000004239 Secondary hypertension Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000009843 endothelial lesion Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000007334 memory performance Effects 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- BOFMSBVSYVESTM-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2C1 BOFMSBVSYVESTM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"4-FLúOR-N-INDAN-2-II-BENZAMIDA E SEU USO FARMACêUTICO". A presente invenção refere-se a 4-flúor-N-indan-2-il-benzamida de acordo com a fórmula (I) e seu uso farmacêutico. O composto (I) pode ser usado para terapia e profilaxia de doenças cardiovasculares como angina do peito estável ou instável, angina de Prinzmetal (espasmo), síndrome coronariana aguda, deficiência cardíaca, infarto do miocárdio, acidente vascular cerebral, trombose, doença oclusiva de artéria periférica PAOD, aterosclerose, restenose, lesão endotelial após PTCA, hipertensão essencial, hipertensão pulmonar, hipertensão secundária, glomerulonefrite renovascular crónica, disfunção erétil, arritmia ventricular e diminuição de risco cardiovascular para mulheres após a menopausa ou após uso de anticoncepcionais; terapia e profilaxia de diabetes ou suas complicações (nefropatia, retinopatia), angiogênese, asma brónquica, deficiência renal crónica, cirrose do fígado, desempenho restrito de memória ou capacidade restrita de aprendizado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01102852 | 2001-02-13 | ||
| PCT/EP2002/001443 WO2002064146A1 (en) | 2001-02-13 | 2002-02-12 | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207178A true BR0207178A (pt) | 2004-03-30 |
Family
ID=8176423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207178-9A BR0207178A (pt) | 2001-02-13 | 2002-02-12 | 4-flúor-n-indan-2-ii-benzamida e seu uso farmacêutico |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6617359B2 (pt) |
| EP (1) | EP1361882B1 (pt) |
| JP (1) | JP4317689B2 (pt) |
| KR (1) | KR101017531B1 (pt) |
| CN (1) | CN100553631C (pt) |
| AT (1) | ATE344669T1 (pt) |
| AU (1) | AU2002253009B2 (pt) |
| BG (1) | BG66065B1 (pt) |
| BR (1) | BR0207178A (pt) |
| CA (1) | CA2437966C (pt) |
| CY (1) | CY1106278T1 (pt) |
| CZ (1) | CZ20032154A3 (pt) |
| DE (1) | DE60215919T2 (pt) |
| DK (1) | DK1361882T3 (pt) |
| EE (1) | EE05302B1 (pt) |
| ES (1) | ES2274025T3 (pt) |
| HK (1) | HK1062140A1 (pt) |
| HR (1) | HRP20030646A2 (pt) |
| HU (1) | HUP0302845A3 (pt) |
| IL (2) | IL157208A0 (pt) |
| MX (1) | MXPA03006841A (pt) |
| MY (1) | MY135778A (pt) |
| NO (1) | NO333522B1 (pt) |
| NZ (1) | NZ527469A (pt) |
| PE (1) | PE20020884A1 (pt) |
| PL (1) | PL363452A1 (pt) |
| PT (1) | PT1361882E (pt) |
| RS (1) | RS51645B (pt) |
| RU (1) | RU2308946C2 (pt) |
| SI (1) | SI1361882T1 (pt) |
| SK (1) | SK286513B6 (pt) |
| TW (1) | TWI241190B (pt) |
| WO (1) | WO2002064146A1 (pt) |
| ZA (1) | ZA200305412B (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020870A1 (es) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| MXPA05004192A (es) | 2002-10-21 | 2005-09-20 | Johnson & Johnson | Tetralinas e indanos sustituidos. |
| AU2003294441A1 (en) * | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| US7132536B2 (en) * | 2003-04-24 | 2006-11-07 | Sanofi-Aventis Deutschland Gmbh | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals |
| ATE384039T1 (de) * | 2003-07-03 | 2008-02-15 | Lilly Co Eli | Indanderivate als muscarinrezeptoragonisten |
| WO2005018620A2 (en) * | 2003-08-26 | 2005-03-03 | Cell Center Cologne Gmbh | Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction |
| EP1529525A1 (en) * | 2003-11-06 | 2005-05-11 | Aventis Pharma Deutschland GmbH | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
| US8309608B2 (en) * | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| PL3138566T3 (pl) * | 2003-11-17 | 2022-03-07 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii z użyciem bh4 |
| AR048931A1 (es) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
| WO2006055511A2 (en) * | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
| EP1814553A4 (en) * | 2004-11-19 | 2009-10-28 | Childrens Hosp Medical Center | GTPASE INHIBITORS AND THEIR USE IN CONTROLLING PLATELET HYPERACTIVITY |
| US20060185492A1 (en) | 2005-02-18 | 2006-08-24 | Francois Chianese | Shoulder bushing for saw blades |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| US7795101B2 (en) * | 2006-04-03 | 2010-09-14 | United Microelectronics Corp. | Method of forming a MOS transistor |
| EP1905764A1 (en) | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
| EP1923062A1 (en) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |
| KR101349187B1 (ko) * | 2006-12-05 | 2014-01-10 | (주)아모레퍼시픽 | 지방대사 이상질환의 치료 및 예방용 약학 조성물 |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| US20160169868A9 (en) * | 2007-05-24 | 2016-06-16 | Calcimedica, Inc. | Calcium channel proteins and uses thereof |
| US20100222334A1 (en) * | 2007-10-09 | 2010-09-02 | Wayne Talamonti | Pharmaceutical Formulation of Valsartan |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| AR088020A1 (es) | 2010-06-30 | 2014-05-07 | Ironwood Pharmaceuticals Inc | Compuestos heterociclicos como estimuladores de sgc |
| CN107266433A (zh) | 2010-11-09 | 2017-10-20 | 铁木医药有限公司 | sGC刺激剂 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN104066731B (zh) | 2011-12-27 | 2016-06-15 | 铁木医药有限公司 | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| ES2774295T3 (es) | 2013-03-15 | 2020-07-20 | Cyclerion Therapeutics Inc | Estimuladores de sGC |
| JP2016540017A (ja) | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激物質 |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| JP2017527604A (ja) | 2014-09-17 | 2017-09-21 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| CN107406422B (zh) | 2014-09-17 | 2022-02-01 | 赛科理音医疗有限公司 | 作为sGC刺激剂的吡唑衍生物 |
| MA45592A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Promédicaments à base de phosphore de stimulateurs de sgc |
| MX2019000115A (es) | 2016-07-07 | 2019-04-22 | Ironwood Pharmaceuticals Inc | Formas solidas de un estimulador de gualinato ciclasa soluble (sgc). |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
| WO2000003746A2 (en) | 1998-07-14 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| AUPP891299A0 (en) * | 1999-02-26 | 1999-03-25 | Fujisawa Pharmaceutical Co., Ltd. | New 6-membered cyclic compounds |
| AU2001264977B2 (en) * | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7105513B2 (en) | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
-
2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/zh not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 AT AT02722066T patent/ATE344669T1/de active
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/ru not_active IP Right Cessation
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/es active IP Right Grant
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/ja not_active Expired - Fee Related
- 2002-02-12 RS YU61703A patent/RS51645B/en unknown
- 2002-02-12 DK DK02722066T patent/DK1361882T3/da active
- 2002-02-12 NZ NZ527469A patent/NZ527469A/xx not_active IP Right Cessation
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/ko not_active IP Right Cessation
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en active IP Right Grant
- 2002-02-12 EE EEP200300368A patent/EE05302B1/xx not_active IP Right Cessation
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 ES ES02722066T patent/ES2274025T3/es not_active Expired - Lifetime
- 2002-02-12 PL PL02363452A patent/PL363452A1/xx not_active Application Discontinuation
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/hu unknown
- 2002-02-12 IL IL15720802A patent/IL157208A0/xx unknown
- 2002-02-12 DE DE60215919T patent/DE60215919T2/de not_active Expired - Lifetime
- 2002-02-12 PT PT02722066T patent/PT1361882E/pt unknown
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/cs unknown
- 2002-02-12 EP EP02722066A patent/EP1361882B1/en not_active Expired - Lifetime
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/pt not_active Application Discontinuation
- 2002-02-12 CN CNB028048636A patent/CN100553631C/zh not_active Expired - Fee Related
- 2002-02-12 SI SI200230443T patent/SI1361882T1/sl unknown
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/sk not_active IP Right Cessation
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/es not_active Application Discontinuation
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
-
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/xx unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/bg unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/no not_active IP Right Cessation
- 2003-08-12 HR HR20030646A patent/HRP20030646A2/hr not_active Application Discontinuation
-
2004
- 2004-06-11 HK HK04104235.3A patent/HK1062140A1/xx not_active IP Right Cessation
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
-
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207178A (pt) | 4-flúor-n-indan-2-ii-benzamida e seu uso farmacêutico | |
| BR0207197A (pt) | 6,7,8,9-tetraidro-5h-benzocicloeptenil aminas aciladas e seu uso como agente farmacêutico | |
| DK1370530T3 (da) | Acyleret 1,2,3,4-tetrahydronaphtylaminer og anvendelse deraf som farmaceutisk produkt | |
| BR0207211A (pt) | Indanil aminas aciladas e seu uso como produtos farmacêuticos | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| BR0314186A (pt) | Derivados de pirimidinona como agentes terapêuticos contra processos inflamatórios, isquêmicos e remodeladores, agudos e crÈnicos | |
| WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
| ES2141197T3 (es) | Derivados del acido fenoxifenilacetico. | |
| WO2006044509A3 (en) | Methods of treating vascular injuries | |
| BR0313240A (pt) | Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos | |
| DE60122928D1 (de) | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat | |
| HK1064374A1 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors. | |
| BR0008310A (pt) | Derivados de alfa-alanina | |
| BR9914893A (pt) | Cromenona e derivados de cromanona como inibidores de integrina | |
| AR035538A1 (es) | 4-fluoro-n-indan-2-il-benzamida para la fabricacion de un medicamento y composiciones farmaceuticas que la comprenden | |
| WO2000048447A3 (en) | Composition for treatment of external secretion disorders except hypolacrimation | |
| AR006408A1 (es) | Derivado de butadieno, derivado de amidobutadieno, derivado de pirrolidina y procesos de preparación de los mismos. | |
| JP2005513067A5 (pt) | ||
| BR0113373A (pt) | Derivados bifenila e o uso dos mesmos como inibidores de integrina | |
| PA8552001A1 (es) | 1,2,3,4-tetrahidronaftil aminas aciladas y su uso como farmacos | |
| PA8551901A1 (es) | Indanil aminas aciladas y su uso como farmacos | |
| PA8552101A1 (es) | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas y su uso como farmacos | |
| WO2004050639A3 (en) | 5-nitroso-6-piperazinyl-pyrimidine derivatives for treating ischemia | |
| WO2006029179A3 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |